Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects With Schizophrenia When Switching From Oral Antipsychotics.
Phase of Trial: Phase III
Latest Information Update: 22 May 2014
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Johnson & Johnson
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jul 2012 Planned end date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 10 Apr 2012 Actual patient number (546) added as reported by ClinicalTrials.gov.